Avience Biomedicals IPO

Upcoming SME

Already have an account? Apply now

Avience Biomedicals IPO details

18th – 22nd Jun 2026
25 Jun 2026
₹196 – ₹208
Lot size 600 — ₹124800
30cr

Schedule of Avience Biomedicals

Issue open date 18 Jun 2026
Issue close date 22 Jun 2026
UPI mandate deadline 22 Jun 2026 (5 PM)
Allotment finalization 23 Jun 2026
Refund initiation 24 Jun 2026
Share credit 24 Jun 2026
Listing date 25 Jun 2026
Mandate end date 07 Jul 2026
Lock-in end date for anchor investors (50%) 22 Jul 2026
Lock-in end date for anchor investors (remaining) 20 Sep 2026

Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.

About Avience Biomedicals

Avience Biomedicals Limited is an Indian healthcare products company engaged in the manufacturing and supply of diagnostic kits, medical devices and related healthcare products. The company began its operations with diagnostic solutions such as Viral Transport Media (VTM) and test kits for diseases including COVID-19, HIV, HBsAg, malaria and dengue. Over time, it expanded its portfolio to include in-vitro diagnostic (IVD) rapid test kits, serology products, biochemistry analysers and biochemistry reagents. The company serves the healthcare sector by providing products used in disease detection, diagnosis and laboratory testing. Its revenue is primarily generated through the sale of these diagnostic and medical device products. Avience Biomedicals operates in the medical devices and diagnostics segment and focuses on offering healthcare solutions across multiple testing and diagnostic categories.


Financials of Avience Biomedicals


Issue size

Funds Raised in the IPO Amount
Total issue size 30.24
Fresh Issue – Proceeds go to the company 30.24

Utilisation of proceeds

Purpose INR crores (%)
Set up a new manufacturing unit at the YEIDA Medical Device Park, Gautam Buddha Nagar, Uttar Pradesh 15.96 (52.78%)
Fund working capital requirements
8.25 (27.28%)
General corporate purposes 6.03 (20%)

Strengths

  • Manufactures a wide range of diagnostic kits, medical devices, analysers and reagents.
  • Serves pathology labs, hospitals, research centres and other healthcare institutions.
  • Holds ISO 9001, ISO 13485, GMP and ZED MSME Gold certifications.
  • Operates a manufacturing facility in Noida with advanced processing capabilities.
  • Has expanded from diagnostic kits to a broader portfolio of healthcare products.

Risks

  • Business performance may be affected by changes in government policies and regulations.
  • Operations depend on the continued services of key management personnel and employees.
  • The company relies on third-party transportation and logistics providers.
  • Market demand and industry fluctuations can impact revenue and profitability.
  • The company has ongoing legal proceedings involving commercial and cheque dishonour matters.